Related Experiment Video

Updated: Feb 22, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K

[After the GEMINI-ACS-1 trial]

Mehmet Birhan Yılmaz1

  • 1Department of Cardiology, Cumhuriyet University Faculty of Medicine, Sivas, Turkey. mehmet.birhan.yilmaz@tkd.org.tr.

Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir
|September 27, 2017
PubMed

Insights

Low dose rivaroxaban demonstrated comparable safety to aspirin for acute coronary syndromes (ACS) patients. This finding offers a potential new antithrombotic strategy for managing ACS, impacting future treatment guidelines.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Acute coronary syndromes (ACS) represent a significant cause of cardiovascular morbidity and mortality.
  • Current management of ACS often involves antithrombotic therapy to prevent thrombotic events.
  • Aspirin is a standard antithrombotic agent, but alternative agents are being investigated.

Purpose of the Study:

  • To evaluate the safety of low-dose rivaroxaban compared to aspirin in patients with ACS.
  • To determine if rivaroxaban offers a non-inferior safety profile to aspirin in this population.

Main Methods:

  • The GEMINI-ACS-1 trial was a prospective clinical study.
  • Patients with ACS were randomized to receive either low-dose rivaroxaban or aspirin.
  • Safety outcomes, including bleeding events, were the primary endpoints.

Main Results:

  • The study assessed the safety and efficacy of rivaroxaban versus aspirin in ACS.
  • Detailed results regarding bleeding rates and other safety parameters were reported.

Conclusions:

  • The GEMINI-ACS-1 trial provides crucial data on the safety of low-dose rivaroxaban in ACS.
  • Findings may influence future antithrombotic treatment strategies for patients with acute coronary syndromes.

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

984
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.1K

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K